Tilvestamab

Names

[ Name ]:
Tilvestamab

Biological Activity

[Description]:

Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> TAM Receptor

[Target]

AXL[1].

[In Vitro]

Tilvestamab (250 µM; 1 h) inhibits AXL phosphorylation in 786-0 cells[1]. Cell Viability Assay[1] Cell Line: 786-0-Luc cells (Gas6- induced; Gas6 is a well characterized AXL ligand) Concentration: 250 µM Incubation Time: 1 h (pre-treat) Result: Drastically inhibited Gas6- induced AXL phosphorylation and decreased the level of pAKT.

[In Vivo]

Tilvestamab (30 mg/kg; i.p.; twice a week) suppresses tumor growth by inhibiting AXL in orthotopic RCC model[1]. Animal Model: Female BALB/c athymic nude mice (8-week-old; orthotopic RCC model)[1]. Dosage: 30 mg/kg Administration: Intraperitoneal injection; twice a week Result: Significantly inhibited RCC growth down to about 1/3 of the volume.

[References]

[1]. Chen TJ, et al. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model. Physiol Rep. 2021 Dec;9(23):e15140.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.